]>
IRCT20191011045057N1 IRCT 2020-02-05 Esfahan University of Medical Sciences Laser in treatment of resistant melasma, Intradermal tranexamic acid in treatment of resistant melasma Comparison of the efficacy of Fractional Erbium: YAG laser and topical hyroquinone 4% versus intradermal tranexamic acid and topical hyroquinone 4% in treatment of resistant melasma 2019-09-22 anticipated 27 Complete https://irct.ir/trial/42949 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block randomization - Individual randomization unit - SPSS statistical software is used for randomization, Blinding description: Those responsible for evaluating the data are blind to the results. These people are unaware of the treatment on each side of the patient's face, so they are blind to this assessment. 2 Melasma. Intervention 1: Intervention group: Laser therapy with topical treatment (4% hydroquinone cream) for the treatment of refractory melasma in one side of a person. Intervention 2: Intervention group: Intranasal injection of tzanexamic acid plus topical treatment (4% hydroquinone cream) to treat refractory melasma on the other side of the same face. No - There is not a plan to make this available Justification or reason for not sharing IPD is Due to the project going on, I still have no decision.
public Bahareh Bahrami
Shahid Keshvari Highway, Sofe Boulevard, Alzahra Medical Center
Isfahan Iran (Islamic Republic of) 8174675731 +98 31 3620 2020 bahar_bahrami45@yahoo.com Esfahan University of Medical Sciences scientific Fateme Mokhtari
Shahid Keshvari Highway, Sofe Boulevard, Alzahra Medical Center
Isfahan Iran (Islamic Republic of) 8174675731 +98 31 3620 2020 f_mokhtari2004@yahoo.com Esfahan University of Medical Sciences Iran (Islamic Republic of) Iran (Islamic Republic of) Female patients with melasma with age ranging from 20 to 50 years Having informed consent to participate in the study No pregnancy or lactation No systemic diseases 20 years 50 years Female Female patients with melasma younger than 20 years and over 50 years Lack of informed consent to participate in the study Pregnancy or lactation Systemic diseases L81.1 Chloasma Treatment - Devices Treatment - Drugs Intervention group: Laser therapy with topical treatment (4% hydroquinone cream) for the treatment of refractory melasma in one side of a person Intervention group: Intranasal injection of tzanexamic acid plus topical treatment (4% hydroquinone cream) to treat refractory melasma on the other side of the same face MASI score. Timepoint: Get started, one month later, two month later, three months later, three months after the end of treatment. Method of measurement: check list and examination. Esfahan University of Medical Sciences Approved 2019-09-23 Ethics Committee of Isfahan University of Medical Sciences Shahid Keshvari Highway, Sofe Boulevard, Alzahra Medical Center Isfahan Isfehan Iran (Islamic Republic of)